Drug patent litigation isn’t just about what’s claimed—it’s about what’s designed around.
In pharma, “design-around” sounds like a clever legal strategy. In practice, it’s a disciplined engineering-and-intelligence exercise: read the claim language l…

Drug patent litigation isn’t just about molecules—it’s about design choices.
In pharma, “design around” sounds like a strategy. In practice, it’s a discipline: a way to translate patent language into formulation decisions, development timelines, and …

Pharma has a $300 billion problem—and it’s not just about patents. It’s about time.
In drug development, “time” is the difference between funding the next pipeline and running out of runway. Yet many companies still treat patent life as a static asset—…

Pharma has a $300B problem—and it’s not just about patents. It’s about time.
In the U.S., the patent system doesn’t merely grant exclusivity; it also tries to compensate for delays outside a drugmaker’s control. That’s where two concepts—patent term ad…

Pharma executives don’t lose in Eurasia because they “missed a filing.” They lose because they misunderstood the rules of the game.
Eurasia is often treated like a secondary market—important, but not urgent. That mindset is expensive.
A recent DrugPate…

Pharma’s patent cliff isn’t just a legal problem—it’s a portfolio problem.
In the boardroom, “patent strategy” often gets treated like a compliance checkbox: file, defend, renew, repeat. But the real question isn’t whether patents exist—it’s whether …

The clock is already ticking—so why are so many market access deals still built like it isn’t?
In pharma, timing isn’t a detail. It’s the deal.
Drug patent cliffs, exclusivity windows, and payer contracting cycles don’t just shape strategy—they determi…

Before You Launch: The Freedom-to-Operate Checklist That Can Save Your Pharma Program
In pharma, the most expensive word isn’t “failure.” It’s “surprise.”
Surprise that a competitor’s patent blocks your launch timeline. Surprise that a “minor” formulat…

Pharma procurement teams are sitting on a quiet risk engine—and most are ignoring it.
Paragraph IV filings are often treated like a legal footnote: something for counsel to track, something for commercial teams to react to, something for finance to “ha…

Drug patents in Asia-Pacific: the protection you think you have vs. the protection you actually get
If you’re a pharma executive, investor, or in-house counsel, you already know the headline numbers: patent terms, regulatory exclusivities, data protect…